PPARs and LXRs: Atherosclerosis goes nuclear

Grant D. Barish, Ronald M. Evans*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

61 Scopus citations


Atherosclerosis is the leading cause of mortality in the Western world, and new therapeutics to target the metabolic and inflammatory factors that underlie its pathogenesis are needed. Peroxisome proliferator-activated receptors and liver X receptors are lipid-activated nuclear receptors that regulate systemic glucose and lipid metabolism, and modulate inflammation within the vascular wall. New understanding of their functions in physiology and the development of high-affinity synthetic ligands highlight their potential as targets for the treatment of cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)158-165
Number of pages8
JournalTrends in Endocrinology and Metabolism
Issue number4
StatePublished - May 2004

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'PPARs and LXRs: Atherosclerosis goes nuclear'. Together they form a unique fingerprint.

Cite this